{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:20:36Z","timestamp":1791177636820,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004856","name":"New York State Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102400","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:42:02Z","timestamp":1594816922000},"page":"102400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Promising recovery biomarkers after first event acute demyelinating optic neuritis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-0460","authenticated-orcid":false,"given":"S.","family":"Klineova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kupersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2020.102400_bib0001","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1167\/iovs.11-9300","article-title":"Patterns of ganglion cell complex and nerve fiber layer loss in nonarteritic ischemic optic neuropathy by Fourier-domain optical coherence tomography","volume":"53","author":"Aggarwal","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.msard.2020.102400_bib0002","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis","author":"Andorra","year":"2019","journal-title":"JAMA Neurol"},{"issue":"16","key":"10.1016\/j.msard.2020.102400_bib0003","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102400_bib0004","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/j.jns.2013.07.1366","article-title":"Alemtuzumab improves visual outcomes in treatment-na\u00efve patients with relapsing\u2013\/INS;remitting multiple sclerosis (RRMS): analysis from the phase 3 care-ms I study","volume":"333","author":"Balcer","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2020.102400_bib0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/1352458517690822","article-title":"Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis","volume":"23","author":"Balcer","year":"2017","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2020.102400_bib0006","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. the optic neuritis study group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2020.102400_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/WNO.0000000000000173","article-title":"Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life","volume":"35","author":"Chahin","year":"2015","journal-title":"J. Neuroophthalmol."},{"issue":"2","key":"10.1016\/j.msard.2020.102400_bib0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamaophthalmol.2018.5398","article-title":"Association of macular visual field measurements with glaucoma staging systems","volume":"137","author":"De Moraes","year":"2019","journal-title":"JAMA Ophthalmol."},{"issue":"Pt 6","key":"10.1016\/j.msard.2020.102400_bib0009","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/brain\/awq080","article-title":"Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration","volume":"133","author":"Green","year":"2010","journal-title":"Brain"},{"issue":"6 PT 2","key":"10.1016\/j.msard.2020.102400_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.26.6_Part_2.26","article-title":"Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States","volume":"26","author":"Ikuta","year":"1976","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102400_bib0011","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archophthalmol.2010.16","article-title":"Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years","volume":"128","author":"Keltner","year":"2010","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2020.102400_bib0012","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1167\/iovs.11-9339","article-title":"Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT","volume":"53","author":"Kupersmith","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.msard.2020.102400_bib0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/1352458515598020","article-title":"Retinal ganglion cell layer thinning within one month of presentation for optic neuritis","volume":"22","author":"Kupersmith","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102400_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102400_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/WNO.0000000000000662","article-title":"Evolution of visual outcomes in clinical trials for multiple sclerosis disease-modifying therapies","volume":"38","author":"Nolan","year":"2018","journal-title":"J. Neuroophthalmol."},{"issue":"2","key":"10.1016\/j.msard.2020.102400_bib0016","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2020.102400_bib0017","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/archophthalmol.2011.352","article-title":"Retinal ganglion cell layer thickness and local visual field sensitivity in glaucoma","volume":"129","author":"Raza","year":"2011","journal-title":"Arch. Ophthalmol."},{"issue":"12","key":"10.1016\/j.msard.2020.102400_bib0018","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/1352458511418630","article-title":"Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness","volume":"17","author":"Saidha","year":"2011","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2020.102400_bib0019","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00415-012-6466-x","article-title":"In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques","volume":"259","author":"Seigo","year":"2012","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2020.102400_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11910-018-0858-y","article-title":"Using the anterior visual system to assess neuroprotection and remyelination in multiple sclerosis trials","volume":"18","author":"Silbermann","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"5","key":"10.1016\/j.msard.2020.102400_bib0021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9394(14)75429-7","article-title":"Contrast sensitivity and other vision tests in the optic neuritis treatment trial","volume":"121","author":"Trobe","year":"1996","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.msard.2020.102400_bib0022","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ophtha.2011.11.032","article-title":"Ganglion cell loss in relation to visual disability in multiple sclerosis","volume":"119","author":"Walter","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.msard.2020.102400_bib0023","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:49Z","timestamp":1761900709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"alternative-id":["S2211034820304752"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102400","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promising recovery biomarkers after first event acute demyelinating optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102400"}}